

Draft Guidance on Acalabrutinib

October 2024

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Acalabrutinib

Dosage Form: Capsule

Route: Oral

Strength: 100 mg

Recommended Study: One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fasting
Design: Single-dose, two-treatment, two-period crossover in vivo
Strength: 100 mg
Subjects: Healthy males and non-pregnant, non-lactating females
Additional comments: Exclude subjects with abnormal liver function tests. Females of reproductive potential should use non-hormonal contraception during the study and continue to use effective contraception for one week after the last dose.

Analytes to measure: Acalabrutinib and active metabolite, M27, in plasma

Submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for area under the curve and maximum concentration.

Bioequivalence based on (90% CI): Acalabrutinib

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, <http://www.accessdata.fda.gov/scripts/cder/dissolution>. Conduct comparative dissolution testing on 12 dosage units for each of the test product and reference listed drug (RLD).¹ Specifications will be determined upon review of the abbreviated new drug application.

Document History: Recommended February 2019; Revised October 2024

Unique Agency Identifier: PSG_210259

¹ If the RLD is not available, refer to the most recent version of the FDA guidance for industry on *Referencing Approved Drug Products in ANDA Submissions*.